Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has been assigned an average recommendation of “Hold” from the ten analysts that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $5.08.

A number of research analysts have issued reports on TNDM shares. B. Riley restated a “neutral” rating and issued a $1.50 price objective on shares of Tandem Diabetes Care in a research note on Wednesday, May 3rd. Zacks Investment Research downgraded Tandem Diabetes Care from a “hold” rating to a “sell” rating in a research note on Wednesday, August 2nd.

Tandem Diabetes Care (TNDM) opened at 0.45 on Friday. The company’s market capitalization is $22.60 million. Tandem Diabetes Care has a 52 week low of $0.39 and a 52 week high of $8.81. The stock’s 50 day moving average is $0.63 and its 200 day moving average is $1.28.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings results on Thursday, July 27th. The medical device company reported ($0.44) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.48) by $0.04. Tandem Diabetes Care had a negative return on equity of 1,177.11% and a negative net margin of 110.70%. The business had revenue of $21.30 million during the quarter, compared to the consensus estimate of $21.74 million. During the same quarter in the prior year, the company posted ($0.60) earnings per share. Tandem Diabetes Care’s revenue was down 7.4% compared to the same quarter last year. Analysts predict that Tandem Diabetes Care will post ($1.79) EPS for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Wrapmanager Inc. boosted its position in shares of Tandem Diabetes Care by 59.2% in the first quarter. Wrapmanager Inc. now owns 96,405 shares of the medical device company’s stock worth $116,000 after buying an additional 35,866 shares in the last quarter. Iguana Healthcare Management LLC boosted its position in shares of Tandem Diabetes Care by 33.3% in the first quarter. Iguana Healthcare Management LLC now owns 100,000 shares of the medical device company’s stock worth $120,000 after buying an additional 25,000 shares in the last quarter. OLD National Bancorp IN boosted its position in shares of Tandem Diabetes Care by 31.0% in the first quarter. OLD National Bancorp IN now owns 119,779 shares of the medical device company’s stock worth $144,000 after buying an additional 28,320 shares in the last quarter. Monashee Investment Management LLC purchased a new position in shares of Tandem Diabetes Care during the first quarter worth approximately $180,000. Finally, Group One Trading L.P. purchased a new position in shares of Tandem Diabetes Care during the first quarter worth approximately $185,000. 45.99% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Tandem Diabetes Care, Inc. (TNDM) Given Average Rating of “Hold” by Analysts” was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another site, it was illegally copied and republished in violation of United States and international copyright & trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/tandem-diabetes-care-inc-tndm-given-average-rating-of-hold-by-analysts/1474280.html.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Analyst Recommendations for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.